Gilbeau Laurent, Kantor Guy, Stoeckle Eberhard, Lagarde Philippe, Thomas Laurence, Kind Michèle, Richaud Pierre, Coindre Jean-Michel, Bonichon Françoise, Bui Binh Nguyen
Radiation Oncology Department, Institut Bergonié, Regional Cancer Center, 229, cours de l'Argonne, 33076 Bordeaux, France.
Radiother Oncol. 2002 Dec;65(3):137-43. doi: 10.1016/s0167-8140(02)00283-9.
Forty-five patients were consecutively treated for primary retroperitoneal soft tissue sarcoma with surgery in combination with radiation therapy in the same institution. The median follow-up time was 53 months (7-108).
Seventeen (38%) patients had clear microscopic margins (R0 resection), 26 patients (58%) had gross complete surgical excision (R1 resection) and two patients (4%) had a macroscopic residual disease (R2 resection). External radiotherapy doses ranged from 40.8 to 59.4 Gy (mean and median: 49 Gy). Seventeen patients underwent intraoperative radiation therapy (IORT). Moreover, 11 patients received chemotherapy. The overall 1-, 2-, and 5-year survival for all 45 patients were 93, 85 and 60%, respectively. The 1-, 2-, and 5-year locoregional relapse-free rate for the whole group was 91, 70 and 40%, respectively. In univariate analysis, quality of surgery was the only variable to show a significant effect for overall survival (P=0.0386) and for local control (P=0.0059). Tumor size and tumor grade had no statistically significant effect. For the patients receiving IORT+external beam radiation therapy, no difference was observed for survival or locoregional control. The most frequent acute side effects treatment complications were radiation-induced nausea or vomiting (42%) and moderate enteritis (30%). Significant late morbidity was observed for two patients.
This study confirms the feasibility of external postoperative radiotherapy with an acceptable level of toxicity. However, the high rate of local relapses (especially in field of radiation) does not demonstrate the usefulness of radiotherapy at the level of dose used and further preferably randomized studies should be planned.
45例原发性腹膜后软组织肉瘤患者在同一机构接受了手术联合放射治疗。中位随访时间为53个月(7 - 108个月)。
17例(38%)患者镜下切缘阴性(R0切除),26例(58%)患者实现大体完全手术切除(R1切除),2例(4%)患者有肉眼残留病灶(R2切除)。外照射剂量范围为40.8至59.4 Gy(平均和中位剂量:49 Gy)。17例患者接受了术中放射治疗(IORT)。此外,11例患者接受了化疗。45例患者的1年、2年和5年总生存率分别为93%、85%和60%。全组的1年、2年和5年局部区域无复发生存率分别为91%、70%和40%。单因素分析中,手术质量是唯一对总生存(P = 0.0386)和局部控制(P = 0.0059)有显著影响的变量。肿瘤大小和肿瘤分级无统计学显著影响。对于接受IORT + 外照射放疗的患者,在生存或局部区域控制方面未观察到差异。最常见的急性副作用治疗并发症是放射性恶心或呕吐(42%)和中度肠炎(30%)。2例患者出现显著的晚期并发症。
本研究证实了术后外照射放疗的可行性及可接受的毒性水平。然而,局部复发率高(尤其是在放疗区域)表明在所用剂量水平的放疗效果不佳,应进一步开展更优的随机研究。